Inhibition of CDK6 by shRNA or pharmacological inhibitor (e.g., PD-0332991) decreases leukemic cell growth and promotes myeloid cell differentiation in cell lines and primary human AML cells harboring different KMT2A translocations. The gene discussed is CDK6; the disease is acute myeloid leukemia.